CJC-1295 is a tetrasubstituted form of human growth hormone-releasing factor (1-29) with an added maleimidopropionamide derivative of lysine at its C-terminus, designed to bind serum albumin after injection and so extend its plasma half-life.
emerging — human data exists, and it is thin or contested
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
CJC-1295 is a tetrasubstituted form of human growth hormone-releasing factor (1-29) with an added maleimidopropionamide derivative of lysine at its C-terminus, designed to bind serum albumin after injection and so extend its plasma half-life. · pmid:15817669
History
In rats it was still present in plasma beyond 72 hours, and a CJC-1295-reactive species appeared on the serum albumin band within 15 minutes of injection. · pmid:15817669
In healthy adults a single subcutaneous injection raised mean growth hormone 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9 to 11 days; its estimated half-life was 5.8 to 8.1 days. · pmid:16352683
Proportion of the 2 claims about CJC-1295 DAC standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for CJC-1295 DAC yet.
Dose evidence, rung by rung
No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
nothing resolved on this rung
Observational evidence· resolved human data at the emerging tier: thin, or contested
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. · pmid 16352683 · 2006
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. · pmid 15817669 · 2005
2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.